Showing results (1211-1220 of 5,058) with videos related to

Sort By:
Pageof 506
Multiple Sclerosis and Related Disorders|July 20, 2018
Myocardial infarction in a patient with multiple sclerosis after receiving natalizumabAala Darki, Peiman Masoumi, Abbas Soleimani, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Multiple Sclerosis and Related Disorders|July 25, 2026
Modified Delphi consensus on the use of cladribine tablets in relapsing-remitting multiple sclerosis in North-West AfricaSmail Daoudi, Houyam Tibar, Chokri Mhiri, et al.
Multiple Sclerosis and Related Disorders|August 1, 2026
Gut microbiota and brain health: Disease-specific pathways and emerging therapeutic strategiesGhaleb Oriquat, Jasur Rizaev, Abdulqader Faris Abdulqader, et al.
Multiple Sclerosis and Related Disorders|July 20, 2026
A scoping review of comorbidity aetiology in multiple sclerosisM Safa, H Riel, M A Krysak, et al.
Multiple Sclerosis and Related Disorders|February 13, 2021
Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosisCarlos R Camara-Lemarroy, Claudia Silva, Luanne M Metz, et al.
Multiple Sclerosis and Related Disorders|July 31, 2026
High early mortality and contributing factors in seropositive neuromyelitis optica spectrum disorder at a tertiary hospital in ZambiaMalya Sahu, Deanna Saylor
Multiple Sclerosis and Related Disorders|July 27, 2026
Acute transverse myelitis excluding MS, NMOSD and MOGAD: A 15-year real-world cohort from IranRana Hashemi, Ehsan Bahrami Hezaveh, Farid Javandoust Gharehbagh, et al.
Multiple Sclerosis and Related Disorders|August 11, 2026
Cyberchondria severity in multiple sclerosis: the role of sociodemographic and clinical factorsFatma Avşar Ertürk, Bülent Güven, Pelin Batmaz Dinç, et al.
Multiple Sclerosis and Related Disorders|August 13, 2026
A matter of formulation: Efficacy and tolerability of nabiximols and cannabis decoction for the treatment of multiple sclerosis-related spasticityArianna Sartori, Anna Favero, Lucrezia Rossi, et al.
Pageof 506